| 0.4551 -0.03 (-6.22%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.35 | 1-year : | 2.03 |
| Resists | First : | 1.16 | Second : | 1.74 |
| Pivot price | 0.44  |
|||
| Supports | First : | 0.22 | Second : | 0.18 |
| MAs | MA(5) : | 0.53 |
MA(20) : | 0.4 |
| MA(100) : | 0.31 |
MA(250) : | 1.21 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 18.4 |
D(3) : | 20.5 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 3.39 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INTS ] has closed below upper band by 49.4%. Bollinger Bands are 537.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.51 | 0.51 - 0.51 |
| Low: | 0.42 - 0.43 | 0.43 - 0.43 |
| Close: | 0.45 - 0.45 | 0.45 - 0.46 |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Fri, 07 Nov 2025
Intensity Therapeutics Shrinks Losses As Cash Runway Extends - Finimize
Thu, 06 Nov 2025
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Fri, 31 Oct 2025
Intensity Therapeutics (Nasdaq: INTS) prices $4M registered direct, selling 5M shares - Stock Titan
Fri, 31 Oct 2025
INTS Stock Price and Chart — NASDAQ:INTS - TradingView
Fri, 31 Oct 2025
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PR Newswire
Fri, 31 Oct 2025
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 12.7 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 2,250 (K) |
| Shares Short P.Month | 254 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -122.7 % |
| Return on Equity (ttm) | -334.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.56 |
| PEG Ratio | 0 |
| Price to Book value | 5.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|